阿托伐他汀钙联合阿司匹林对冠心病的治疗效果与安全性

Efficacy and safety of atorvastatin calcium combined with aspirin in the treatment of coronary heart disease

目的 探讨阿托伐他汀钙联合阿司匹林对冠心病治疗效果与安全性.方法 将2011年1月至2016年1月收治的180例冠心病患者按照随机数字表法分为观察组和对照组,每组90例,在氧疗、美托洛尔、缬沙坦、硝酸异山梨酯治疗的基础上,对照组采用阿司匹林（100 mg,1次/d）治疗.观察组采用阿托伐他汀钙（20 mg,1次/d）＋阿司匹林（100 mg,1次/d）治疗.比较两组疗效、血脂水平、高敏C-反应蛋白（hs-CRP）、一氧化氮（nitricoxide,NO）及内皮素-1（endothelin 1,ET-1）.结果 观察组总有效率显著高于对照组（86.7%比68.9%,x2=8.229,P〈0.05）,心电图总有效率显著高于对照组（91.1%比75.6%,x2=7.840,P〈0.05）.治疗后,观察组甘油三酯、胆固醇及低密度脂蛋白水平均显著低于对照组（t=13.763、14.755、7.017,均P〈0.05）,hs-CRP[（1.99±0.36）mg/L比（3.76±0.42）mg/L]及ET-1水平[（4.27±0.63）mg/L比（5.14±0.56）mg/L]均显著低于对照组,NO水平[（73.73±12.54）mmol/L比（64.34±11.73）mmol/L]显著高于对照组（t=30.355、5.188、9.792,均P〈0.05）.两组不良反应差异无统计学意义（x2=1.098,P〉0.05）.结论 在冠心病的治疗中,阿托伐他汀钙联合阿司匹林具有良好的效果,且安全性高.

Objective To investigate the efficacy and safety of atorvastatin calcium combined with aspirin in the treatment of coronary heart disease.Methods 180 patients with coronary heart disease were randomly divided into observation group and control group according to the random number table method from January 2011 to January 2016,90 cases in each group.On the basis of the treatment of oxygen therapy,the treatment of metoprolol,valsartan,the control group was treated with aspirin （100mg,1 time/d）,and the observation group was treated with atorvastatin （20mg,1 time/d） ＋ aspirin （100mg,1 time/d）.The efficacy,blood lipid levels,the level of high-sensitivity C-reactive protein （hs-CRP）,nitric oxide （NO） and endothelin-1 （ET-1） were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group （86.7% vs.68.9%,x2=8.229,P〈0.05）.The total effective rate of ECG in the observation group was significantly higher than that in the control group （x2=7.840,P〈0.05）.After treatment,the levels of triglyceride,cholesterol and low density lipoprotein in the observation group were significantly lower than those in the control group,hs-CRP [（1.99±0.36）mg/L vs.（3.76±0.42）mg/L] and ET-1 levels [（4.27±0.63）mg/L vs.（5.14±0.56）mg/L] were significantly lower than those in the control group（t=13.763,14.755,7.017,all P〈0.05）,NO level [（73.73±12.54）mmol/L vs.（64.34±11.73）mmol/L] was significantly higher than that in control group （t=30.355,5.188,9.792,all P〈0.05）.There was no significant difference in adverse reactions between the two groups （x2=1.098,P〉0.05）.Conclusion Atorvastatin calcium combined with aspirin has good effect in the treatment of coronary heart disease,and has high security.